ATE74273T1 - Zusammensetzung aus antikoagulantia. - Google Patents

Zusammensetzung aus antikoagulantia.

Info

Publication number
ATE74273T1
ATE74273T1 AT89100852T AT89100852T ATE74273T1 AT E74273 T1 ATE74273 T1 AT E74273T1 AT 89100852 T AT89100852 T AT 89100852T AT 89100852 T AT89100852 T AT 89100852T AT E74273 T1 ATE74273 T1 AT E74273T1
Authority
AT
Austria
Prior art keywords
anticoagulant
anticoagulants
composition
activity
heparin
Prior art date
Application number
AT89100852T
Other languages
German (de)
English (en)
Inventor
Keizo Hirahara
Original Assignee
Hoechst Japan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11897770&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE74273(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoechst Japan filed Critical Hoechst Japan
Application granted granted Critical
Publication of ATE74273T1 publication Critical patent/ATE74273T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Paper (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
AT89100852T 1988-01-28 1989-01-19 Zusammensetzung aus antikoagulantia. ATE74273T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP63015761A JP2739050B2 (ja) 1988-01-28 1988-01-28 抗血液凝固剤
EP89100852A EP0326014B1 (en) 1988-01-28 1989-01-19 Composition of anticoagulants

Publications (1)

Publication Number Publication Date
ATE74273T1 true ATE74273T1 (de) 1992-04-15

Family

ID=11897770

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89100852T ATE74273T1 (de) 1988-01-28 1989-01-19 Zusammensetzung aus antikoagulantia.

Country Status (13)

Country Link
US (1) US5084273A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0326014B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP2739050B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR0127754B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE74273T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU607303B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1330299C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE68901098D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK37789A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2039709T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR3005040T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (1) IE63528B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT89534B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8822147D0 (en) * 1988-09-21 1988-10-26 Ciba Geigy Ag Pharmaceutically active combination
SE464135B (sv) * 1989-07-14 1991-03-11 Kabivitrum Ab Foerfarande foer bestaemning av funktionell aktivitet av fritt protein s eller protein c i ett plasmaprov
US5571786A (en) * 1990-08-16 1996-11-05 Immuno Aktiengesellschaft Use of protein C or the activation peptide of protein C for preparing a pharmaceutical preparation
AT402260B (de) * 1990-08-16 1997-03-25 Immuno Ag Protein c-hältige pharmazeutische präparation
FR2671973A1 (fr) * 1991-01-25 1992-07-31 Fondation Nale Transfusion San Utilisation de la proteine c activee comme agent anti-agregant plaquettaire.
AT402263B (de) * 1991-06-20 1997-03-25 Immuno Ag Pharmazeutische präparation enthaltend eine thrombolytisch wirkende substanz
EP0651655A4 (en) 1992-07-24 1996-05-29 Oklahoma Med Res Found REDUCTION OF MICROVASCULAR BLEEDING DURING SURGERY BY BLOCKING PROTEIN C ACTIVATION
KR100330540B1 (ko) * 1993-04-05 2002-09-04 웰파이드 코포레이션 안티트롬빈-iii액상제제및그안정화방법
DE4320294A1 (de) * 1993-06-18 1994-12-22 Immuno Ag Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen
US5516889A (en) * 1993-06-21 1996-05-14 University Technologies International, Inc. Synthetic thrombin receptor peptides
AU2467395A (en) * 1994-05-04 1995-11-29 Board Of Trustees Of The University Of Arkansas, The Novel ophthalmologic uses of protein c
JPH08224227A (ja) * 1995-02-22 1996-09-03 Internatl Reagents Corp 血液採血管
US6562781B1 (en) 1995-11-30 2003-05-13 Hamilton Civic Hospitals Research Development Inc. Glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
US6491965B1 (en) 1995-11-30 2002-12-10 Hamilton Civic Hospitals Research Development, Inc. Medical device comprising glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
US7045585B2 (en) * 1995-11-30 2006-05-16 Hamilton Civic Hospital Research Development Inc. Methods of coating a device using anti-thrombin heparin
US6630137B1 (en) 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
JP4383546B2 (ja) 1997-04-28 2009-12-16 イーライ・リリー・アンド・カンパニー 活性化プロテインｃの改良プロセシング方法
PL337223A1 (en) * 1997-06-05 2000-08-14 Lilly Co Eli Method of treating thrombotic disorders
GB9711927D0 (en) * 1997-06-09 1997-08-06 Bristol Myers Squibb Co Compositions useful as fibrin sealants
US7204981B2 (en) 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
AU2001262939A1 (en) 2000-05-24 2001-12-03 Eli Lilly And Company Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states
DE10045047A1 (de) 2000-09-12 2002-03-21 Beate Kehrel Arzneimittel enthaltend aktiviertes Antithrombin III
JP2004535461A (ja) * 2001-07-19 2004-11-25 ディーエムアイ バイオサイエンシズ インコーポレイテッド プロテインｃの不活性化を抑制するための銅キレート剤の使用
EP1485121A4 (en) * 2002-03-08 2007-11-07 Lilly Co Eli ACTIVE C PROTEIN FORMULATIONS
EP2239320A4 (en) * 2008-01-29 2012-04-25 Kyowa Hakko Kirin Co Ltd ACCELERATOR OF NERVOUS TRUNK CELL PROPAGATION
WO2024003418A1 (en) 2022-07-01 2024-01-04 Universiteit Maastricht Improved downregulation of histone cytotoxicity by complex of negatively charged polysaccharide and protease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8319538D0 (en) * 1983-07-20 1983-08-24 Beecham Group Plc Compounds
US5084274A (en) 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism

Also Published As

Publication number Publication date
US5084273A (en) 1992-01-28
AU607303B2 (en) 1991-02-28
EP0326014B1 (en) 1992-04-01
DK37789D0 (da) 1989-01-27
GR3005040T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1993-05-24
JPH01193229A (ja) 1989-08-03
IE890269L (en) 1989-07-28
CA1330299C (en) 1994-06-21
ES2039709T3 (es) 1993-10-01
AU2885589A (en) 1989-08-03
DE68901098D1 (de) 1992-05-07
PT89534B (pt) 2001-05-31
KR0127754B1 (ko) 1998-04-01
DK37789A (da) 1989-07-29
PT89534A (pt) 1989-10-04
JP2739050B2 (ja) 1998-04-08
IE63528B1 (en) 1995-05-03
KR890011606A (ko) 1989-08-21
EP0326014A1 (en) 1989-08-02

Similar Documents

Publication Publication Date Title
ATE74273T1 (de) Zusammensetzung aus antikoagulantia.
SE8000469L (sv) Vevnadsbindmedel och forfarande for dess framstellning samt bindmedlets anvendning
FI905003A0 (fi) Glykosaminoglykan modifierat protein.
KR870700004A (ko) 하나이상의 활성성분을 가지는 살충제 조성물
NO166871C (no) Termoplastiske blandinger.
IT1140999B (it) Glicosaminoglicani modificati dotati di attivita' antilipemica e privi di attivita' anticoagulante
DE3871036D1 (de) Leistungsregelung von kombianlagen.
IT8447964A1 (it) Complessi d'inclusione, loro preparazione e loro impiego come insetticidi.
DE68907083D1 (de) Abkoemmlinge von 2-cyclopentenon.
DK191089D0 (da) Biologisk aktive forbindelser
DE3583698D1 (de) Perkutaner absorptions-beschleuniger und diesen enthaltendes praeparat.
ATE44640T1 (de) Schaedlingsbekaempfungsmittel.
DE3675069D1 (de) Carboxanilide.
IT8021337A0 (it) Nuove frazioni di eparina dotate di maggiore attivita' anticoagulante e procedimento per ottenerle.
AU4266289A (en) Antidote
KR910700061A (ko) 인터로이킨-1β의 안정화 조성물
DE3888543D1 (de) Zusammensetzungen zur herstellung von gasdurchlässigen kontaktlinsen.
DK181089A (da) 1-dimethylcarbamoyl-3-substituerede-5-substituerede-1h-1,2,4-triazoler
DK44184D0 (da) Kosmetik
FI915571A0 (fi) Trombinbindande substans och foerfarande foer dess framstaellning.
DE69909010D1 (de) Verwendung von procyanidolischen Oligomeren oder Anthocyanosiden als Anti-Urease Wirkstoffe
IT8721325A0 (it) Procedimento e agente per combattere la tignola crociata della vite.
IT8622051A1 (it) Composizioni farmaceutiche ad attivita' cicatrizzante
ATE87967T1 (de) Zusammensetzung eines zusatzes.
FI854460A0 (fi) Flytande, biologiskt aktiva sammansaettningar.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
RZN Patent revoked